Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.

Author: Yogor Digar
Country: Bhutan
Language: English (Spanish)
Genre: Life
Published (Last): 11 October 2013
Pages: 426
PDF File Size: 11.35 Mb
ePub File Size: 8.15 Mb
ISBN: 856-2-28314-222-3
Downloads: 9175
Price: Free* [*Free Regsitration Required]
Uploader: Dailar

Because of the rarity of the disease, there is no established standard therapy. In the year has been indexed in the Medlinedatabase, and has become a vehicle espelnico expressing the most current Spanish medicine and modern. Twelve patients received maintenance rituximab therapy and 11 of them had no evidence of progression after a median follow-up of 28 months.

Ocasional presencia discreta de componente M en suero. Valorar profilaxis con fluconazol mg po.

Orphanet: Linfoma esplenico de la zona marginal

Low dose 2CdA schedule activity in splenic marginal zone lymphomas. This time, an inguinal mass was palpable. Rituximab monotherapy for splenic marginal zone lymphoma.

Here, we present two patients whose disease recurred after splenectomy and for whom rituximab monotherapy provided satisfactory treatment.

Recientes estudios parecen confirmar la heterogeneidad molecular de este conjunto de enfermedades. Linfoma B esplenicoo la zona marginal. Only comments written in English can be processed.


The immunophenotype was compatible with SMZL with villous lymphocytes. Watch and wait con vigilancia cada meses: All four had relapsed after, or failed to respond to, recommended first-line therapies.

Two out three patients, who received pentostatin as first line therapy, ttained a complete esplneico CR. Using these 3 variables, we grouped patients into 3 prognostic categories: The median 10 Grupo Asturiano de Linfomas Noviembre duration between diagnosis and treatment was 17 months range, Considering the lack of established data regarding this rare and clinically challenging issue, we made a systematic search for indexed articles published on this topic.

Procesos linfoproliferativos no Hodgkin de células B

Pueden registrarse remisiones prolongadas en los tumores de bajo grado. The patient was promptly subjected to splenectomy, which confirmed the diagnosis of SMZL infiltration.

Incluye localizaciones ganglionares y extraganglionares, enfermedades primarias y secundarias.

All patients were assessable: Further, we present information regarding the molecular biological and clinical characteristics of these lymphomas. Clinicopathological definition of Waldenstrom’s macroglobulinemia: Cell cycle deregulation in B-cell lymphomas. Health care resources for this disease Expert centres Diagnostic tests 59 Patient organisations 45 Orphan drug s The workup revealed disease in the peripheral blood and bone marrow and massive splenomegaly.

The material is in no way intended to replace professional medical esplejico by a qualified specialist and should not be used as a basis for diagnosis or treatment.

From our search in the PubMed database using the terms ” rituximab AND marginal zone B cell lymphoma AND therapy”, we found papers, of which six were related to the current topic. Go to martinal members area of the website of the AEDV, https: Summary and related texts.


Linfoma esplénico de la zona marginal:

Signs and symptoms, mostly related to ypersplenism, are successfully managed by splenectomy. SMZL is an indolent lymphoma usually treated by esplehico. The category of diffuse large B-cell lymphoma is heterogeneous, including several subtypes.

CiteScore measures average citations received per document published.

Linfoma esplénico de la zona marginal:

Chapter 3 – University of Alberta. This case demonstrates that rituximab monotherapy might also be a valid therapeutic approach in marginal zone lymphoma and autoimmune hemolytic anemia after failure of first-line treatment. The Integruppo Italiano Linfomi IIL carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in patients. Eleven of them had no evidence of disease progression after a maarginal follow-up time of Nevertheless, these observations need to be validated with studies containing a larger group of patients.

CD 10 y bcl-6, la t 14; Variable frequencies of t 11;18 q21;q21 in MALT lymphomas of different sites: